Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OptiMedica, an ophthalmic company, has appointed Stephen Hanlon as its new vice president of R&D. In this newly created position, Mr Hanlon will be responsible for driving new technology and product innovation for the company.
Subscribe to our email newsletter
Mr Hanlon was previously vice president of R&D for Boston Scientific’s neurovascular division, where he oversaw a 100-person multi-disciplinary department and numerous successful product launches.
Prior to Boston Scientific, he served as vice president of operations for Photoelectron as well as vice president and general manager of the radionics division of Tyco Healthcare (now Covidien).
Mark Forchette, president and CEO of OptiMedica, said: “Steve’s deep medical technology experience and proven track record of innovation make him the perfect choice to lead OptiMedica’s substantial R&D efforts as we develop new additions to our growing portfolio of products.
“We look forward to working with Steve to accelerate the development of new technologies and products that meet the highest standards of excellence in the ophthalmic industry.”